Drusen in patient-derived hiPSC-RPE models of macular dystrophies.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28878022)

Published in Proc Natl Acad Sci U S A on September 06, 2017

Authors

Chad A Galloway¹^,2, Sonal Dalvi¹^,2, Sandy S C Hung³^,4^,5, Leslie A MacDonald¹^,2, Lisa R Latchney¹, Raymond C B Wong³^,4^,5, Robyn H Guymer³^,4^,5, David A Mackey⁶, David S Williams⁷^,8^,9^,10^,11, Mina M Chung¹^,12, David M Gamm¹³^,14^,15, Alice Pébay³^,4^,5, Alex W Hewitt³^,4^,5^,16^,17, Ruchira Singh¹⁸^,2^,12

Author Affiliations

1: Department of Ophthalmology, University of Rochester, Rochester, NY 14642.
2: Department of Biomedical Genetics, University of Rochester, Rochester, NY 14642.
3: Centre for Eye Research Australia, East Melbourne, VIC 3002, Australia.
4: Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia.
5: Ophthalmology, Department of Surgery, The University of Melbourne, Parkville VIC 3010, Australia.
6: Centre of Ophthalmology and Visual Science, Lions Eye Institute, University of Western Australia, Crawley, Western Australia, Australia.
7: Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
8: Jules Stein Eye Institute, University of California, Los Angeles, CA 90095.
9: Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
10: Molecular Biology Institute, University of California, Los Angeles, CA 90095.
11: Brain Research Institute, University of California, Los Angeles, CA 90095.
12: Center for Visual Science, University of Rochester, Rochester, NY 14642.
13: Waisman Center, University of Wisconsin, Madison, WI 53705.
14: McPherson Eye Research Institute, University of Wisconsin, Madison, WI 53706.
15: Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI 53706.
16: Menzies Institute for Medical Research, University of Tasmania, Hobart TAS 7005, Australia.
17: School of Medicine, University of Tasmania, Hobart TAS 7005, Australia.
18: Department of Ophthalmology, University of Rochester, Rochester, NY 14642; ruchira_singh@urmc.rochester.edu.

Articles cited by this ↗

Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98

Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 6.47

Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J (2000) 6.40

A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol (2002) 5.57

The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46

Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci (1996) 3.69

Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proc Natl Acad Sci U S A (2009) 3.53

The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res (2009) 3.40

A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet (1999) 3.32

Pathophysiology of age-related macular degeneration. Surv Ophthalmol (1987) 3.17

Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet (1994) 3.11

Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells (2009) 2.70

Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol (2006) 2.67

Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci (1989) 2.44

Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med (2012) 2.37

Histopathology of age-related macular degeneration. Mol Vis (1999) 2.27

Optic vesicle-like structures derived from human pluripotent stem cells facilitate a customized approach to retinal disease treatment. Stem Cells (2011) 2.26

Transcriptome analysis and molecular signature of human retinal pigment epithelium. Hum Mol Genet (2010) 2.20

The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem (1995) 1.70

Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 1.67

Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol (2001) 1.64

A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell (2016) 1.60

iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration. Hum Mol Genet (2012) 1.59

Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res (2009) 1.56

Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: a model for the early pathogenic course of macular degeneration. Hum Mol Genet (2007) 1.54

Blood-derived human iPS cells generate optic vesicle-like structures with the capacity to form retinal laminae and develop synapses. Invest Ophthalmol Vis Sci (2012) 1.50

The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. Hum Mol Genet (2007) 1.47

Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration. J Lipid Res (2009) 1.41

Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE. Stem Cells (2011) 1.39

Sorsby's fundus dystrophy. A light and electron microscopic study. Ophthalmology (1989) 1.38

Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem (2004) 1.32

Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.30

Attainment of polarity promotes growth factor secretion by retinal pigment epithelial cells: relevance to age-related macular degeneration. Aging (Albany NY) (2009) 1.28

Cholesterol in the retina: the best is yet to come. Prog Retin Eye Res (2014) 1.27

Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med (2012) 1.24

Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J Biol Chem (1999) 1.23

Regulated expression of apolipoprotein E by human retinal pigment epithelial cells. J Lipid Res (2003) 1.23

Assessment of the phenotypic range seen in Doyne honeycomb retinal dystrophy. Arch Ophthalmol (1997) 1.19

Premature aggregation of type IV collagen and early lethality in lysyl hydroxylase 3 null mice. Proc Natl Acad Sci U S A (2004) 1.15

Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol (1998) 1.14

Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am J Pathol (1997) 1.10

S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis. J Biol Chem (2009) 1.08

Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. J Biol Chem (2007) 1.07

Functional analysis of serially expanded human iPS cell-derived RPE cultures. Invest Ophthalmol Vis Sci (2013) 1.07

Induced Pluripotent Stem Cells Meet Genome Editing. Cell Stem Cell (2016) 1.06

Validation of genome-wide association study (GWAS)-identified disease risk alleles with patient-specific stem cell lines. Hum Mol Genet (2014) 1.06

Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects. Mol Ther (2014) 1.05

Clinical course and treatment outcomes of Sorsby fundus dystrophy. Am J Ophthalmol (2008) 1.01

Tissue inhibitor of metalloproteinases 3 regulates extracellular matrix--cell signaling during bronchiole branching morphogenesis. Dev Biol (2006) 1.00

Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol (2010) 1.00

Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula. Br J Ophthalmol (1992) 1.00

TIMP-3 is expressed in the human retinal pigment epithelium. Biochem Biophys Res Commun (1996) 0.97

A mouse model for Sorsby fundus dystrophy. Invest Ophthalmol Vis Sci (2002) 0.96

Subretinal Pigment Epithelial Deposition of Drusen Components Including Hydroxyapatite in a Primary Cell Culture Model. Invest Ophthalmol Vis Sci (2017) 0.96

Disturbed matrix metalloproteinase activity of Bruch's membrane in age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 0.91

Age-related macular degeneration and changes in the extracellular matrix. Med Sci Monit (2014) 0.88

Bisretinoid-mediated complement activation on retinal pigment epithelial cells is dependent on complement factor H haplotype. J Biol Chem (2014) 0.84

Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration. Hum Mol Genet (2013) 0.83

Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures. Exp Eye Res (2013) 0.83

A local complement response by RPE causes early-stage macular degeneration. Hum Mol Genet (2015) 0.79

Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports (2017) 0.77

Human pluripotent stem cell strategies for age-related macular degeneration. Optom Vis Sci (2014) 0.76

Friedreich's ataxia induced pluripotent stem cell-derived cardiomyocytes display electrophysiological abnormalities and calcium handling deficiency. Aging (Albany NY) (2017) 0.76

Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. Cell Stem Cell (2017) 0.75

Rescue of the MERTK phagocytic defect in a human iPSC disease model using translational read-through inducing drugs. Sci Rep (2017) 0.75

Articles by these authors ⇆

Publication output target for ophthalmology subspecialty fellows in Australia. Clin Experiment Ophthalmol (2017) 0.75